New PET scan targets hidden cancers with precision
NCT ID NCT06852638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer and then have a scan to see how well it lights up tumors. The goal is to see if this method is better than standard scans for diagnosing these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radioactive tracers ([18F]RCCB6, [18F]R8B4, [68Ga]R8B4) that bind to CD70 on cancer cells
- What this could lead to
- If successful, this imaging method could help doctors detect certain cancers more accurately and guide treatment decisions.
- What could go wrong
- This is a Phase 2 trial, so it is still early. The tracers may not reliably distinguish all cancer types, and results may not apply to other cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can engineered immune cells tackle brain lymphoma?